Profusa / NorthView Acquisition Corp. Form 10-K Summary
Important identity note: The supplied filing is NorthView Acquisition Corp.’s Form 10-K, not a Form 10-K filed by Profusa, Inc. NorthView was a blank-check company pursuing a merger with Profusa. Reporting period: fiscal year ended December 31, 2023; filed February 23, 2024.
Business context and reporting period
NorthView was formed to complete a business combination and had no operating business or revenue. It intended to focus on healthcare innovation. The proposed transaction would merge Profusa into a NorthView subsidiary, with Profusa surviving as a wholly owned subsidiary and NorthView changing its name to Profusa, Inc. The transaction remained subject to closing conditions, including a minimum available-cash condition, regulatory approvals, and stockholder approvals; completion was not assured.
Financial results and liquidity
| Metric | FY 2023 | FY 2022 |
|---|---|---|
| Operating revenue | None | None |
| Operating costs | $1.51 million | $1.27 million |
| Net income | $1.16 million | $7.17 million |
| Trust-account interest income | $2.25 million | $2.58 million |
| Cash used in operating activities | $2.06 million | $0.58 million |
FY 2023 net income also included a $701,148 gain from changes in warrant fair value and a $177,697 gain from changes in the convertible note’s fair value; these non-operating items contributed to reported profit. Income-tax provision was $456,790. The filing reports no operating revenue, so operating margins are not meaningful.
At December 31, 2023, cash outside the trust was $4,519 and working capital deficit was $3.35 million. The balance sheet reported $9.31 million of trust assets outside current assets and $1.57 million of trust assets classified as current and payable to redeeming holders, or approximately $10.87 million in total trust assets before that redemption payment. Current liabilities were $4.92 million, including $1.86 million excise tax payable, $1.57 million common stock to be redeemed, and a $944,118 fair-value carrying amount for the convertible note. Warrant liabilities were $156,639. No long-term debt or lease obligations were reported.
Material changes versus the prior period
- Net income fell to $1.16 million from $7.17 million, chiefly because the prior-year warrant fair-value gain was substantially larger ($6.36 million in 2022 versus $701,148 in 2023).
- Operating costs rose to $1.51 million from $1.27 million; cash used in operations increased to $2.06 million from $581,189.
- NorthView redeemed 18,000,868 public shares in March 2023 and another 140,663 in December 2023. At year-end, 833,469 public shares remained outstanding; total shares outstanding were 6,027,219 after the December redemption.
- The company recorded a $1.86 million excise-tax liability related to share redemptions.
Transaction, outlook, risks, and unusual items
- The merger agreement values Profusa at a pre-transaction equity value of $155 million, using an assumed NorthView share value of $10. Profusa stockholders may be eligible for up to 3,875,000 additional earnout shares tied to share-price milestones and other conditions.
- Amendment No. 2, dated January 12, 2024, replaced the 2024 revenue earnout milestone of $11.864 million with a requirement to consummate the proposed Tasly joint venture and receive related funding during 2024. The 2025 revenue earnout milestone remains $99.702 million. The agreement’s outside date was extended to June 22, 2024.
- The charter combination period was extended to March 22, 2024. The filing states that failure to complete a business combination by the applicable deadline could require liquidation; management and the auditor identified substantial doubt about NorthView’s ability to continue as a going concern. The filing does not describe a completed extension beyond March 22.
- In February 2024, NorthView authorized a binding term sheet for a proposed $5 million investment by Vellar in Profusa securities at $2 per share, to be funded immediately before the business-combination closing. This was a proposed financing, not reported as completed. The merger’s stated minimum available-cash condition is $15 million.
- NorthView had received a Nasdaq deficiency notice for not holding an annual stockholders’ meeting within the required period. The notice was not an imminent delisting determination; NorthView said it expected to submit a compliance plan, with no assurance of success.
- In January 2024, NorthView directed that trust funds be held in an interest-bearing demand deposit account rather than Treasury investments, potentially reducing interest earned. The filing also flags possible trust-account creditor claims, redemption-related dilution, sponsor conflicts, financing uncertainty, and the possibility that public shares could be liquidated while rights and warrants expire worthless if no transaction closes.
Key facts investors should verify
- Whether the NorthView–Profusa business combination closed, and the actual closing date, final terms, approvals, and available cash.
- Whether the proposed $5 million Vellar investment and Tasly joint venture were completed, and whether the transaction’s minimum-cash condition was satisfied.
- The status of the March 22, 2024 combination deadline, the June 22, 2024 merger-agreement outside date, and any subsequent extensions or amendments.
- Final trust-account proceeds and redemption amounts, including payment of the $1.57 million redemption liability, the excise-tax liability, and any claims against the trust.
- NorthView’s Nasdaq compliance status and the potential dilution from earnout shares, warrants, rights, financing, and any sponsor-convertible note.